Peptide record

TPDB05321

Antibacterial Antiviral Hemolysis Toxicity standard
18 amino acids
Basic Information
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.
TPDB05321
Antibacterial Antiviral Hemolysis Toxicity
Anti-infective peptides Toxicity and safety peptides
AntiBP3 Peptipedia AI4AVP dbAMP 3.0 DRAVP 2.0 HemoPI Hemolytic2 PD_Hemolysis
standard
No
A 18-aa standard-residue multi-activity (Antibacterial, Antiviral, Hemolysis, and other sources) peptide sequence curated from AntiBP3, Peptipedia, AI4AVP, and other sources, with an available 3D structural model.
Sequence
SWLRDIWDWVCEVLSDFK
Physicochemical Analysis

Sequence-only estimates for a linear peptide with free termini, not experimentally measured molecular properties. Mass and formula exclude cyclization and disulfide formation. The optical estimates assume paired cysteines, 280 nm, 1 g/L and a 1 cm path. The N-end rule estimate is not a measured plasma half-life.

C108H153N25O29S1
ANQGHMPTY
DW
2297.61
3.97
2
4
9
-2
1.45
-0.050
97.22
Mammalian: 1.9 hour Yeast: >20 hour E.coli: >10 hour
16500
7.18
3
Residue Composition
number
0
A
1
R
0
N
3
D
1
C
1
E
0
Q
0
G
0
H
1
I
2
L
1
K
0
M
1
F
0
P
2
S
0
T
3
W
0
Y
2
V
Amino Acid Distribution
A: 0 R: 1 N: 0 D: 3 C: 1 E: 1 Q: 0 G: 0 H: 0 I: 1 L: 2 K: 1 M: 0 F: 1 P: 0 S: 2 T: 0 W: 3 Y: 0 V: 2
Chemical Descriptors
18 reviewed residue count
C108H153N25O29S1 sequence-only estimate (linear, free termini)
2297.61 sequence-only estimate (linear, free termini)
3.97 sequence-only estimate (linear, free termini)
-2 sequence-only estimate (linear, free termini)
1.45 sequence-only estimate (linear, free termini)
-0.050 sequence-only estimate (linear, free termini)
Evidence Records 4 records
Evidence 1 Activity

Activity

MHC
Hemolysis
13.93 µM
[Ref.21801309]Human erythrocytes:MHC=13.93 µM.

Target

Human erythrocytes

Source & Reference

Hemolytik PD_Hemolysis
DRAMP4
Chem Biol Drug Des. 2011 Nov 78(5):835-43.

Other

Source Activity Label Source Definition
Hemolysis
Hemolytik experimentally validated hemolytic peptide annotation.
Evidence 2 Activity

Activity

0% Hemolysis
Toxicity
13.93 µM
Hemolytic Cytotoxic
0% Hemolysis | 13.93 | µM | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Rational design of peptides with anti-HCV/HIV activities and enhanced specificity. | Chem Biol Drug Des | 2011
Evidence 3 Activity

Activity

MHC
Toxicity
13.93 µM
Hemolytic
Hemolytic_activity: [Ref.21801309]Human erythrocytes:MHC=13.93 µM.

Target

erythrocytes

Source & Reference

NA
DRAMP
Chem Biol Drug Des. 2011 Nov 78(5):835-43.
Evidence 4 Hemolysis

Activity

13.93 µM
MHC
[Ref.21801309]Human erythrocytes:MHC=13.93 µM.
Hemolysis

Target

Human erythrocytes

Source & Reference

HemoPI PD_Hemolysis
Chem Biol Drug Des. 2011 Nov 78(5):835-43.
DRAMP4
PD_Hemolysis